Willow BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Willow a Legitimate Telehealth Company?

Willow operates as a cash-pay telehealth platform and holds the structural hallmarks of a legal telemedicine business: it connects patients with licensed prescribers, routes prescriptions to licensed pharmacies, and operates a website disclosing its services. Those features do not automatically make a company trustworthy or clinically rigorous, but they place it in the regulated space rather than the black market.

The more precise question is whether Willow meets the transparency and compliance standards that federal and state regulators expect of telehealth companies prescribing controlled or closely scrutinized drugs such as semaglutide and tirzepatide.

What "Legit" Means in the Telehealth Context

Legitimate telehealth companies share a core set of markers. Prescribers must hold active, unrestricted licenses in every state where they see patients. Pharmacies filling compounded GLP-1 drugs must be registered as either a 503A compounding pharmacy or a 503B outsourcing facility with the FDA [1]. Patient consultations must meet the standard of care, which the American Telemedicine Association describes as "the same standard that would apply in an in-person encounter" [2].

Willow's website lists prescriber credentials and references licensed pharmacy partners, which satisfies the surface-level transparency test. Whether every prescriber is actively licensed in every patient's state is something a patient can verify independently through the National Plan and Provider Enumeration System (NPPES) at npiregistry.cms.hhs.gov.

LegitScript Certification Gap

LegitScript is a third-party monitoring service whose certification is the de facto trust signal for online pharmacy and telehealth sites. Google, Meta, and Visa all use LegitScript approval as a requirement for paid advertising of prescription drug services. As of July 2025, a search of the LegitScript database at legitscript.com does not return a certified listing for Willow's primary domain.

That gap does not mean Willow is illegal. Many legitimate telehealth brands operate without LegitScript certification. The absence does mean patients cannot rely on that independent vetting layer, and it means Willow may face advertising restrictions on major platforms.

Willow BBB Profile: What the Complaint File Shows

The Better Business Bureau is not a government regulator, and a low BBB rating does not equal fraud. Still, the BBB complaint file offers a structured, time-stamped record of consumer disputes that government complaint databases often lack.

Accreditation Status

As of the July 2025 review date, Willow does not hold BBB accreditation. Accreditation is voluntary and fee-based, so its absence tells you little about product quality. What it does mean is that Willow has not committed to the BBB's eight standards of trust, which include a requirement to respond to all complaints within 14 days [3].

Complaint Volume and Categories

The public BBB file for Willow shows fewer than 10 closed complaints as of mid-2025. That number is low in absolute terms. For context, large telehealth companies with hundreds of thousands of active patients regularly accumulate 50 to 300 annual BBB complaints.

The complaint categories visible in the file cluster around two themes:

• Billing and subscription cancellation. Customers report difficulty canceling recurring charges after they decided to stop treatment. This is the single most common complaint type for subscription-model telehealth companies across the board.
• Delayed shipment or no shipment. Several complaints reference orders placed but not received, consistent with the broader supply-chain disruptions that hit compounded semaglutide providers throughout late 2023 and 2024.

The table below maps Willow's complaint profile against the three complaint categories the FTC tracks for online health subscriptions, based on publicly available BBB data and consumer review aggregators as of July 2025.

| Complaint Category | Willow BBB File | FTC Category Match | |---|---|---| | Billing / subscription | Yes (majority) | "Negative option / subscription trap" | | Product not received | Yes (minority) | "Fulfillment failure" | | Clinical concern / adverse event | Not visible in public file | "Safety / efficacy" |

The absence of visible clinical adverse-event complaints is a positive data point, though it could also reflect low patient volume, underreporting, or complaints routed directly to state medical boards rather than the BBB.

How Willow's Complaint Density Compares

Complaint density (complaints per estimated active patient) matters more than raw complaint volume. Because Willow does not publish patient-count figures, a precise density calculation is not possible. What is possible: relative to well-established GLP-1 telehealth platforms that carry hundreds of BBB complaints, Willow's public file looks thin. That could mean fewer patients, better operations, or both.

FDA Regulatory Exposure for Compounded GLP-1 Drugs

This section matters for any patient considering Willow because the FDA's posture toward compounded semaglutide shifted materially in early 2025.

The Shortage List and Its Removal

Compounded semaglutide occupied a legal gray zone for most of 2023 and 2024 because semaglutide (Ozempic, Wegovy) appeared on the FDA's drug shortage list. During a shortage, 503A and 503B facilities can legally compound copies of listed drugs [4]. The FDA removed semaglutide from the shortage list in March 2025, which means 503A pharmacies could no longer legally compound semaglutide after a grace period ending May 22, 2025 [5].

503B outsourcing facilities received a separate, later deadline. The FDA issued guidance in March 2025 stating that 503B facilities had until a later enforcement discretion date to wind down bulk semaglutide compounding, though active litigation from compounding pharmacy trade groups complicated the enforcement timeline [6].

Any telehealth brand, including Willow, that continued filling compounded semaglutide orders after the applicable deadline without a patient-specific 503A exemption or a valid 503B status faces regulatory risk. Patients should ask Willow directly: which pharmacy fulfills your prescription, what is that pharmacy's FDA registration number, and is it 503A or 503B?

Salt-Form Products (Semaglutide Acetate, Semaglutide Sodium)

A documented concern across the compounded GLP-1 market is the use of non-base semaglutide salts. The FDA-approved drug uses semaglutide base. Some compounders substitute semaglutide acetate or semaglutide sodium, which the FDA explicitly stated are different active ingredients and may not be compounded under the same shortage authority [7]. If a Willow prescription is filled with a salt form, that represents a regulatory and potential safety issue. Ask the pharmacy for the Certificate of Analysis specifying the active pharmaceutical ingredient.

State Medical Board and Prescriber License Verification

How Telehealth Prescribing Jurisdiction Works

Under the Ryan Haight Online Pharmacy Consumer Protection Act, controlled substances generally require an in-person evaluation before remote prescribing. GLP-1 agonists such as semaglutide and tirzepatide are not controlled substances, so the Ryan Haight Act does not apply. However, each state's medical practice act still governs whether a prescriber can see a patient in that state [8].

The Interstate Medical Licensure Compact (IMLC) allows physicians to hold expedited licenses in member states, but not every Willow prescriber may participate. A prescriber licensed only in Florida cannot legally treat a patient located in California, even via telehealth.

How to Verify Your Prescriber

1. Get your prescriber's full name and NPI number from your Willow patient portal.
2. Search the NPI on the CMS NPPES registry.
3. Cross-check the license number against your state medical board's public lookup tool.
4. Confirm no disciplinary actions are listed.

This three-step check takes under five minutes and applies to any telehealth company, not just Willow.

Consumer Review Patterns Outside the BBB

The BBB is one data source. A complete picture of Willow's consumer-complaint trends requires looking at other aggregators.

Trustpilot and Google Reviews

As of mid-2025, Willow carries a Trustpilot profile with ratings skewing toward 4 and 5 stars, driven heavily by recent reviews. The pattern of a sudden surge in high ratings followed by isolated 1-star reviews describing cancellation difficulties is consistent with what the FTC calls "review gating," where only satisfied customers are directed to review pages [9]. That observation is not evidence of fraud; it is a signal to read the 1-star reviews specifically, because they often contain the most diagnostic information about operational problems.

The 1-star reviews on both Trustpilot and Google for Willow repeat two themes already flagged in the BBB file: difficulty canceling and inconsistent fulfillment. Neither theme involves clinical harm, which is notable. No cluster of adverse event reports appears in the public consumer review record as of this writing.

Reddit and Patient Community Signals

Threads in r/Semaglutide and r/GLP1 from late 2024 and early 2025 contain sporadic Willow mentions. The complaints there mirror the billing and fulfillment themes. More substantively, several threads discuss receiving a telehealth intake questionnaire that did not involve a synchronous video visit, raising questions about whether the standard-of-care requirement for individualized prescribing was met. A telehealth consultation consisting solely of an asynchronous questionnaire occupies a regulatory gray zone in several states, including New York, which requires a real-time interaction for the establishment of a prescriber-patient relationship [10].

Clinical Quality Signals: What Complaint Data Does Not Capture

Consumer complaints are a lagging, biased, and incomplete indicator of clinical quality. Patients who are harmed and do not know they were harmed never complain. Patients who receive mediocre care but lose weight may leave five-star reviews.

What Good GLP-1 Prescribing Looks Like

The Obesity Society and the American Association of Clinical Endocrinologists (AACE) both recommend that GLP-1 therapy be initiated only after a formal assessment of BMI, comorbidities, contraindications (personal or family history of medullary thyroid carcinoma or MEN2), and concurrent medications [11]. The AACE 2023 clinical practice guideline specifies a minimum evaluation that includes measurement of fasting glucose, HbA1c, lipid panel, and thyroid function in patients with obesity [12].

A cash-pay telehealth intake that skips lab work and relies solely on self-reported BMI does not meet that standard, regardless of whether it generates a valid prescription under state law.

Ask Willow before subscribing: Does the intake require recent lab work? Is the prescriber reviewing it before approving a GLP-1? Will there be ongoing monitoring visits?

Dose Titration and Safety Monitoring

Standard GLP-1 titration for semaglutide follows the schedule studied in STEP-1 (N=1,961): 0.25 mg weekly for four weeks, 0.5 mg for four weeks, then escalation toward 2.4 mg over 16 to 20 weeks [13]. Patients who cannot tolerate nausea at any step should have their dose held or reduced. A telehealth platform that auto-ships escalating doses without a clinical check-in at each titration step is not following the evidence base.

The STEP-1 trial produced 14.9% mean body-weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo (P<0.001) [13]. Those results come from a protocol with rigorous monitoring. Real-world compounded-semaglutide platforms that skip monitoring may not replicate that efficacy or safety profile.

What to Do If You Have a Willow Complaint

If you have already had a negative experience with Willow, you have several independent channels for escalation beyond leaving a review.

File with the FTC

The FTC's Consumer Sentinel Network (reportfraud.ftc.gov) accepts complaints about billing practices, subscription traps, and deceptive advertising. FTC data feeds into enforcement actions and annual reports [14].

File with Your State Attorney General

Most state AGs maintain a consumer protection division. Telehealth billing complaints have triggered multi-state investigations of other subscription health companies. Filing takes under 10 minutes at your state AG's website.

Report a Prescribing Concern to the State Medical Board

If you believe a clinical decision (a prescription issued without adequate evaluation) put you at risk, file a complaint with the state medical board where your prescriber is licensed. Boards are required to investigate and respond.

Report Compounding Quality Issues to the FDA

The FDA's MedWatch program (fda.gov/safety/medwatch) accepts reports of suspected product quality problems with compounded drugs, including wrong concentration, contamination, or incorrect active ingredient [15].

Red Flags to Watch For Before You Subscribe to Any GLP-1 Telehealth Platform

The complaint patterns visible in Willow's public file are not unique to Willow. They appear across the cash-pay GLP-1 telehealth sector. A practical checklist for any platform:

• Pharmacy identification. Can the platform tell you the specific pharmacy name and FDA registration number before you pay?
• Salt-form disclosure. Does the pharmacy's Certificate of Analysis confirm semaglutide base, not a salt?
• Prescriber license verification. Is the prescriber licensed in your state?
• Lab work requirement. Does the intake require a lab panel or accept only self-report?
• Cancellation terms in writing. Is the cancellation policy documented in the terms of service before checkout?
• Titration monitoring. Is there a scheduled clinical check-in at each dose escalation step?

Any platform that cannot answer those six questions clearly should not have access to your credit card.